CDMO Samsung Biologics Pursues Expansion on Multiple Fronts as Samsung Group Increases Investment in Biotechnology


In May 2022, it was reported that Samsung Group will increase its spending by more than 30% to $360 billion, investing in its diverse business lines ranging from electronics to biotechnology. As the biotech arm of Samsung Group, Samsung Biologics — a leading contract development and manufacturing organization (CDMO) — will look to utilize this … Read more